vs

Side-by-side financial comparison of ALTISOURCE PORTFOLIO SOLUTIONS S.A. (ASPS) and Pulmonx Corp (LUNG). Click either name above to swap in a different company.

ALTISOURCE PORTFOLIO SOLUTIONS S.A. is the larger business by last-quarter revenue ($42.3M vs $20.6M, roughly 2.1× Pulmonx Corp). ALTISOURCE PORTFOLIO SOLUTIONS S.A. runs the higher net margin — -16.8% vs -66.3%, a 49.5% gap on every dollar of revenue. On growth, ALTISOURCE PORTFOLIO SOLUTIONS S.A. posted the faster year-over-year revenue change (3.2% vs -8.7%). Over the past eight quarters, ALTISOURCE PORTFOLIO SOLUTIONS S.A.'s revenue compounded faster (3.6% CAGR vs -0.5%).

Altisource Portfolio Solutions S.A. is a global provider of integrated technology, data and operational services for the mortgage, real estate and consumer finance sectors. It serves lenders, servicers and investors, offering solutions that streamline asset management and residential property transaction workflows to boost operational efficiency.

Pulmonx Corp is a global medical tech firm focused on interventional pulmonology solutions. It develops minimally invasive endobronchial valves to treat severe COPD and emphysema, with products sold across North America, Europe, and Asia-Pacific for patients with advanced lung conditions.

ASPS vs LUNG — Head-to-Head

Bigger by revenue
ASPS
ASPS
2.1× larger
ASPS
$42.3M
$20.6M
LUNG
Growing faster (revenue YoY)
ASPS
ASPS
+11.9% gap
ASPS
3.2%
-8.7%
LUNG
Higher net margin
ASPS
ASPS
49.5% more per $
ASPS
-16.8%
-66.3%
LUNG
Faster 2-yr revenue CAGR
ASPS
ASPS
Annualised
ASPS
3.6%
-0.5%
LUNG

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ASPS
ASPS
LUNG
LUNG
Revenue
$42.3M
$20.6M
Net Profit
$-7.1M
$-13.7M
Gross Margin
26.5%
77.9%
Operating Margin
-15.5%
-40.9%
Net Margin
-16.8%
-66.3%
Revenue YoY
3.2%
-8.7%
Net Profit YoY
18.2%
5.5%
EPS (diluted)
$-1.02
$-0.33

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASPS
ASPS
LUNG
LUNG
Q1 26
$20.6M
Q4 25
$42.3M
$22.6M
Q3 25
$41.9M
$21.5M
Q2 25
$43.3M
$23.9M
Q1 25
$43.4M
$22.5M
Q4 24
$41.0M
$23.8M
Q3 24
$40.5M
$20.4M
Q2 24
$39.1M
$20.8M
Net Profit
ASPS
ASPS
LUNG
LUNG
Q1 26
$-13.7M
Q4 25
$-7.1M
$-10.4M
Q3 25
$-2.3M
$-14.0M
Q2 25
$16.7M
$-15.2M
Q1 25
$-5.3M
$-14.4M
Q4 24
$-8.7M
$-13.2M
Q3 24
$-9.3M
$-14.1M
Q2 24
$-8.3M
$-15.3M
Gross Margin
ASPS
ASPS
LUNG
LUNG
Q1 26
77.9%
Q4 25
26.5%
77.6%
Q3 25
27.1%
74.7%
Q2 25
30.1%
72.1%
Q1 25
30.7%
72.5%
Q4 24
30.3%
74.0%
Q3 24
29.8%
73.7%
Q2 24
32.5%
73.7%
Operating Margin
ASPS
ASPS
LUNG
LUNG
Q1 26
-40.9%
Q4 25
-15.5%
-43.8%
Q3 25
1.2%
-66.9%
Q2 25
7.5%
-62.0%
Q1 25
7.5%
-64.6%
Q4 24
1.4%
-56.5%
Q3 24
2.7%
-69.3%
Q2 24
5.3%
-75.2%
Net Margin
ASPS
ASPS
LUNG
LUNG
Q1 26
-66.3%
Q4 25
-16.8%
-46.1%
Q3 25
-5.5%
-64.9%
Q2 25
38.5%
-63.6%
Q1 25
-12.1%
-64.1%
Q4 24
-21.3%
-55.4%
Q3 24
-23.0%
-69.4%
Q2 24
-21.1%
-73.7%
EPS (diluted)
ASPS
ASPS
LUNG
LUNG
Q1 26
$-0.33
Q4 25
$-1.02
$-0.25
Q3 25
$-0.22
$-0.34
Q2 25
$1.48
$-0.38
Q1 25
$-0.09
$-0.36
Q4 24
$-4.72
$-0.33
Q3 24
$-2.61
$-0.36
Q2 24
$-2.33
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASPS
ASPS
LUNG
LUNG
Cash + ST InvestmentsLiquidity on hand
$26.6M
$61.6M
Total DebtLower is stronger
$191.1M
$37.3M
Stockholders' EquityBook value
$-110.2M
$45.8M
Total Assets
$139.8M
$120.0M
Debt / EquityLower = less leverage
0.82×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASPS
ASPS
LUNG
LUNG
Q1 26
$61.6M
Q4 25
$26.6M
$69.8M
Q3 25
$28.6M
$76.5M
Q2 25
$30.0M
$75.5M
Q1 25
$30.8M
$74.6M
Q4 24
$29.8M
$70.9M
Q3 24
$28.3M
$63.3M
Q2 24
$29.7M
$63.5M
Total Debt
ASPS
ASPS
LUNG
LUNG
Q1 26
$37.3M
Q4 25
$191.1M
$37.1M
Q3 25
$192.5M
$37.1M
Q2 25
$193.9M
$37.1M
Q1 25
$195.0M
$37.2M
Q4 24
$230.5M
$37.2M
Q3 24
$37.2M
Q2 24
$37.2M
Stockholders' Equity
ASPS
ASPS
LUNG
LUNG
Q1 26
$45.8M
Q4 25
$-110.2M
$54.1M
Q3 25
$-104.2M
$60.0M
Q2 25
$-102.7M
$69.1M
Q1 25
$-119.8M
$77.7M
Q4 24
$-157.4M
$85.8M
Q3 24
$-149.4M
$93.9M
Q2 24
$-140.8M
$101.2M
Total Assets
ASPS
ASPS
LUNG
LUNG
Q1 26
$120.0M
Q4 25
$139.8M
$129.3M
Q3 25
$139.9M
$138.3M
Q2 25
$142.9M
$147.2M
Q1 25
$145.7M
$150.7M
Q4 24
$143.6M
$162.8M
Q3 24
$144.5M
$167.4M
Q2 24
$146.6M
$172.6M
Debt / Equity
ASPS
ASPS
LUNG
LUNG
Q1 26
0.82×
Q4 25
0.69×
Q3 25
0.62×
Q2 25
0.54×
Q1 25
0.48×
Q4 24
0.43×
Q3 24
0.40×
Q2 24
0.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASPS
ASPS
LUNG
LUNG
Operating Cash FlowLast quarter
$-505.0K
Free Cash FlowOCF − Capex
$-525.0K
FCF MarginFCF / Revenue
-1.2%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-5.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASPS
ASPS
LUNG
LUNG
Q1 26
Q4 25
$-505.0K
$-7.1M
Q3 25
$718.0K
$-8.2M
Q2 25
$-306.0K
$-3.9M
Q1 25
$-5.0M
$-13.2M
Q4 24
$-1.4M
$-6.7M
Q3 24
$-1.6M
$-7.2M
Q2 24
$180.0K
$-5.8M
Free Cash Flow
ASPS
ASPS
LUNG
LUNG
Q1 26
Q4 25
$-525.0K
$-7.1M
Q3 25
$697.0K
$-8.3M
Q2 25
$-309.0K
$-4.0M
Q1 25
$-5.0M
$-13.5M
Q4 24
$-1.4M
$-6.8M
Q3 24
$-7.7M
Q2 24
$-6.2M
FCF Margin
ASPS
ASPS
LUNG
LUNG
Q1 26
Q4 25
-1.2%
-31.4%
Q3 25
1.7%
-38.4%
Q2 25
-0.7%
-16.6%
Q1 25
-11.5%
-60.0%
Q4 24
-3.4%
-28.8%
Q3 24
-37.6%
Q2 24
-30.0%
Capex Intensity
ASPS
ASPS
LUNG
LUNG
Q1 26
Q4 25
0.0%
0.1%
Q3 25
0.1%
0.4%
Q2 25
0.0%
0.2%
Q1 25
0.1%
1.3%
Q4 24
0.0%
0.5%
Q3 24
0.0%
2.0%
Q2 24
0.0%
2.3%
Cash Conversion
ASPS
ASPS
LUNG
LUNG
Q1 26
Q4 25
Q3 25
Q2 25
-0.02×
Q1 25
Q4 24
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASPS
ASPS

Services$39.9M94%
Revenue Relatedto Technology Platformsand Professional Services$2.4M6%

LUNG
LUNG

Segment breakdown not available.

Related Comparisons